Literature DB >> 17280577

Does dopamine dysfunction drive depression?

G S Malhi1, M Berk.   

Abstract

OBJECTIVE: To examine the evidence that dopamine (DA) dysfunction contributes to melancholic depression.
METHOD: Database (EMBASE, PsychLit and MEDLINE) searches using relevant key words were conducted and citations were scrutinized.
RESULTS: In this paper, we assume that the definition of melancholia is contingent upon the presence of psychomotor disturbance (PMD). In melancholic depression PMD comprises both a cognitive and motor component and DA is found to be important in both. DA neurotransmission modulates cognition in particular in attention, adaptation and motivational processes and has a pivotal role in motor function.
CONCLUSION: DA is a credible aetiological candidate for the PMD in melancholic depression. However, melancholia needs first to be characterized both clinically and in terms of its pathophysiology. In this regard, illnesses such as bipolar depression and Parkinson's disease warrant consideration as they provide suitable models of both the cognitive and motor aspects of PMD, and hold the necessary markers to better define melancholia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17280577     DOI: 10.1111/j.1600-0447.2007.00969.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  20 in total

Review 1.  New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.

Authors:  Michael Maes; Zdenĕk Fišar; Miguel Medina; Giovanni Scapagnini; Gabriel Nowak; Michael Berk
Journal:  Inflammopharmacology       Date:  2012-01-24       Impact factor: 4.473

2.  Melancholia: restoration in psychiatric classification recommended.

Authors:  Max Fink; Tom G Bolwig; Gordon Parker; Edward Shorter
Journal:  Acta Psychiatr Scand       Date:  2007-02       Impact factor: 6.392

Review 3.  Sleep disturbance as transdiagnostic: consideration of neurobiological mechanisms.

Authors:  Allison G Harvey; Greg Murray; Rebecca A Chandler; Adriane Soehner
Journal:  Clin Psychol Rev       Date:  2010-04-24

Review 4.  The Neuro-Immune Pathophysiology of Central and Peripheral Fatigue in Systemic Immune-Inflammatory and Neuro-Immune Diseases.

Authors:  Gerwyn Morris; Michael Berk; Piotr Galecki; Ken Walder; Michael Maes
Journal:  Mol Neurobiol       Date:  2015-01-20       Impact factor: 5.590

Review 5.  Convergence and divergence in the etiology of myelin impairment in psychiatric disorders and drug addiction.

Authors:  Yue Feng
Journal:  Neurochem Res       Date:  2008-04-11       Impact factor: 3.996

Review 6.  From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.

Authors:  Chiara Fabbri; Stefano Porcelli; Alessandro Serretti
Journal:  Can J Psychiatry       Date:  2014-02       Impact factor: 4.356

7.  Striatal dopamine D2 receptors in medication-naive patients with major depressive disorder as assessed with [11C]raclopride PET.

Authors:  Jussi Hirvonen; Hasse Karlsson; Jaana Kajander; Juha Markkula; Helena Rasi-Hakala; Kjell Någren; Jouko K Salminen; Jarmo Hietala
Journal:  Psychopharmacology (Berl)       Date:  2008-02-05       Impact factor: 4.530

8.  Effects of subclinical depression on prefrontal-striatal model-based and model-free learning.

Authors:  Suyeon Heo; Yoondo Sung; Sang Wan Lee
Journal:  PLoS Comput Biol       Date:  2021-05-14       Impact factor: 4.475

9.  Association of smoking status, cumulative smoking, duration of smoking cessation, age of starting smoking, and depression in Korean adults.

Authors:  Woo-Jun Yun; Min-Ho Shin; Sun-Seog Kweon; So-Yeon Ryu; Jung-Ae Rhee
Journal:  BMC Public Health       Date:  2012-08-31       Impact factor: 3.295

10.  Tobacco smoking predicts depression and poorer quality of life in heart disease.

Authors:  Lesley Stafford; Michael Berk; Henry J Jackson
Journal:  BMC Cardiovasc Disord       Date:  2013-05-24       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.